Back to top

Image: Bigstock

Has ResMed (RMD) Outpaced Other Medical Stocks This Year?

Read MoreHide Full Article

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. ResMed (RMD - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of RMD and the rest of the Medical group's stocks.

ResMed is one of 895 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. RMD is currently sporting a Zacks Rank of #2 (Buy).

Over the past three months, the Zacks Consensus Estimate for RMD's full-year earnings has moved 3.29% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Based on the latest available data, RMD has gained about 2.15% so far this year. In comparison, Medical companies have returned an average of -11.98%. As we can see, ResMed is performing better than its sector in the calendar year.

Breaking things down more, RMD is a member of the Medical - Products industry, which includes 82 individual companies and currently sits at #51 in the Zacks Industry Rank. Stocks in this group have lost about 15.28% so far this year, so RMD is performing better this group in terms of year-to-date returns.

Going forward, investors interested in Medical stocks should continue to pay close attention to RMD as it looks to continue its solid performance.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


ResMed Inc. (RMD) - free report >>

Published in